Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 18/20 | 1.00 |
| ▸ | HTR1B | P28222 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 1.00 |
| ▸ | HTR1D | P28221 | 5/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | HTR5A | P47898 | 2/20 | 0.78 |
| ▸ | HTR2B | P41595 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.78 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-258741 SCHEMBL4459020 | 1.00 | HTR7 (1.00) | HTR7HTR1BDRD3HTR1ADRD2 | |
| SCHEMBL375475 | 0.88 | HTR7 (1.00) | HTR7HTR1BDRD3HTR1ADRD2 | |
| SCHEMBL4298542 | 0.88 | HTR7 (1.00) | HTR7HTR1BDRD3HTR1ADRD2 | |
| SCHEMBL4298546 | 0.88 | HTR7 (1.00) | HTR7HTR1BDRD3HTR1ADRD2 | |
| SCHEMBL375474 | 0.88 | HTR7 (1.00) | HTR7HTR1BDRD3HTR1ADRD2 | |
| SCHEMBL5809435 | 0.88 | HTR7 (0.78) | HTR7HTR1BDRD3HTR1ADRD2 | |
| SCHEMBL17195119 | 0.87 | HTR7 (0.77) | HTR7HTR1BDRD3HTR1ADRD2 | |
| SCHEMBL14117920 | 0.87 | HTR7 (0.77) | HTR7HTR1BDRD3HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL2719588 | 0.87 | HTR7 (1.00) | HTR7HTR1BDRD3HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL2719586 | 0.87 | HTR7 (1.00) | HTR7HTR1BDRD3HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2052251-B1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-07 | — | — | EP | claimed |
| US-8883808-B2 | Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | claimed |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | BONAVENTURE PASCAL | 2009-11-05 | — | — | US | claimed |
| EP-0912512-B1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-02 | — | — | EP | claimed |
| US-6265408-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANT | SMITHKLINE BEECHAM PLC (GB) | 2001-07-24 | — | — | US | claimed |
| EP-0912512-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1997048681-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | claimed |
| US-12558412-B2 | Vaccination of immunocompromised subjects | Seqirus UK Limited (GB) | 2026-02-24 | — | — | US | disclosed |
| US-20250269008-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250242011-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | Seqirus UK Limited (GB) | 2025-07-31 | — | — | US | disclosed |
| US-20240342267-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | SEQIRUS UK LTD (GB) | 2024-10-17 | — | — | US | disclosed |
| EP-4144369-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | Seqirus UK Limited (GB) | 2023-03-08 | — | — | EP | disclosed |
| US-11406701-B2 | Vaccination of immunocompromised subjects | Seqirus UK Limited (GB) | 2022-08-09 | — | — | US | disclosed |
| US-8883808-B2 | Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | disclosed |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | BONAVENTURE PASCAL | 2009-11-05 | — | — | US | disclosed |
| US-20060199978-A1 | Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-0912512-B1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-6265408-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANT | SMITHKLINE BEECHAM PLC (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912512-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048681-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199978-A1 | Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders | HTR7, HTR4, CHRM5 | HTR7 1/4885HTR1B 10/4885DRD3 89/4885 |
| US-12558412-B2 | Vaccination of immunocompromised subjects | ICOS, IL15, CD4 | HTR7 4035/4885HTR1B 4257/4885DRD3 2725/4885 |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | HTR7, HTR1A, HTR6 | HTR7 1/4885HTR1B 11/4885DRD3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.